Marco Di Pascoli
Overview
Explore the profile of Marco Di Pascoli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
567
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Esposito M, Buono R, Angeli P, Girardi P, Di Pascoli M
Dig Liver Dis
. 2024 Dec;
PMID: 39672771
Background: The global prevalence of Metabolic Dysfunction-Associated Liver Disease is dramatically increasing with the diffusion of cardiometabolic risk factors (CMRFs). The aim of the present study was to assess the...
2.
Girardi P, Buono R, Bisazza C, Marchi L, Angeli P, Di Pascoli M
Dig Liver Dis
. 2023 Oct;
56(5):810-817.
PMID: 37845154
Background: In patients with cirrhosis, infections significantly increase the risk of short and long-term mortality. During infection, the levels of procalcitonin increase, but it has not yet been clarified its...
3.
Turkseven S, Turato C, Villano G, Ruvoletto M, Guido M, Bolognesi M, et al.
Antioxidants (Basel)
. 2023 Apr;
12(4).
PMID: 37107346
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. NAFLD can evolve from simple fatty liver to non-alcoholic steatohepatitis (NASH), and ultimately, to cirrhosis. Inflammation and oxidative...
4.
Pepe V, Angeli P, Di Pascoli M
Clin Exp Gastroenterol
. 2022 May;
15:59-65.
PMID: 35492075
Background: At the present time, in patients with liver cirrhosis and gastroesophageal varices, primary prophylaxis of variceal bleeding made with combination therapy with non-selective β-blockers (NSBBs) and endoscopic band ligation...
5.
Turkseven S, Bolognesi M, Di Pascoli M
Dig Dis Sci
. 2020 Apr;
66(3):796-801.
PMID: 32242304
Background: In liver cirrhosis, a marked splanchnic vasodilation causes an increase in portal blood flow, contributing to the development of portal hypertension. Aim: To evaluate if, in experimental cirrhosis, a...
6.
Turkseven S, Bolognesi M, Brocca A, Pesce P, Angeli P, Di Pascoli M
Am J Physiol Gastrointest Liver Physiol
. 2019 Dec;
318(2):G298-G304.
PMID: 31813234
In liver cirrhosis, oxidative stress plays a major role in promoting liver inflammation and fibrosis. Mitochondria dysregulation is responsible for excessive reactive oxygen species production. Therefore, in an experimental model...
7.
Villano G, Verardo A, Martini A, Brocco S, Pesce P, Novo E, et al.
Ann Hepatol
. 2019 Oct;
19(1):36-43.
PMID: 31607648
Introduction And Objectives: SerpinB3 is a cysteine protease inhibitor involved in several biological activities. It is progressively expressed in chronic liver disease, but not in normal liver. The role in...
8.
Di Pascoli M, Fasolato S, Piano S, Bolognesi M, Angeli P
Liver Int
. 2018 Sep;
39(1):98-105.
PMID: 30230204
Background & Aims: In patients with cirrhosis, the clinical benefit of the treatment with human albumin for ascites is debated, and no data are available regarding refractory ascites. In this...
9.
Di Pascoli M, La Mura V
Dig Liver Dis
. 2018 Sep;
51(2):297-298.
PMID: 30220630
No abstract available.
10.
Di Pascoli M, Sacerdoti D, Pontisso P, Angeli P, Bolognesi M
J Vasc Res
. 2017 Apr;
54(2):92-99.
PMID: 28402977
In liver cirrhosis, portal hypertension is a consequence of enhanced intrahepatic vascular resistance and portal blood flow. Significant vasodilation in the arterial splanchnic district is crucial for an increase in...